OCUP Stock Overview
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ocuphire Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.67 |
| 52 Week High | US$6.60 |
| 52 Week Low | US$1.67 |
| Beta | 0.24 |
| 1 Month Change | -12.57% |
| 3 Month Change | -38.83% |
| 1 Year Change | -72.89% |
| 3 Year Change | -66.06% |
| 5 Year Change | n/a |
| Change since IPO | -72.17% |
Recent News & Updates
Recent updates
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15
Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Ocuphire drops 11% on $15M at-the money direct offering
Jun 04Ocuphire Pharma EPS beats by $0.36
May 07Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?
Feb 08Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Jan 06Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Jan 05Shareholder Returns
| OCUP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.7% | -2.3% | -3.7% |
| 1Y | -72.9% | 11.4% | 20.2% |
Return vs Industry: OCUP underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: OCUP underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| OCUP volatility | |
|---|---|
| OCUP Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OCUP's share price has been volatile over the past 3 months.
Volatility Over Time: OCUP's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 14 | George Magrath | www.ocuphire.com |
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
Ocuphire Pharma, Inc. Fundamentals Summary
| OCUP fundamental statistics | |
|---|---|
| Market cap | US$41.44m |
| Earnings (TTM) | -US$9.99m |
| Revenue (TTM) | US$19.05m |
2.2x
P/S Ratio-4.1x
P/E RatioIs OCUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCUP income statement (TTM) | |
|---|---|
| Revenue | US$19.05m |
| Cost of Revenue | US$1.08m |
| Gross Profit | US$17.97m |
| Other Expenses | US$27.96m |
| Earnings | -US$9.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 94.36% |
| Net Profit Margin | -52.42% |
| Debt/Equity Ratio | 0% |
How did OCUP perform over the long term?
See historical performance and comparison